Cicil Biochem Profile
Key Indicators
- Authorised Capital ₹ 5.63 Cr
as on 23-10-2024
- Paid Up Capital ₹ 5.63 Cr
as on 23-10-2024
- Company Age 13 Year, 11 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 8.71 Cr
as on 23-10-2024
- Satisfied Charges ₹ 38.00 Cr
as on 23-10-2024
- Revenue 2.75%
(FY 2023)
- Profit 140.36%
(FY 2023)
- Ebitda -2.46%
(FY 2023)
- Net Worth -0.19%
(FY 2023)
- Total Assets -0.73%
(FY 2023)
About Cicil Biochem
The Corporate was formerly known as Cicil Biochem Private Limited. The Company is engaged in the Food And Beverages Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.63 Cr and a paid-up capital of Rs 5.63 Cr.
The company currently has active open charges totaling ₹8.71 Cr. The company has closed loans amounting to ₹38.00 Cr, as per Ministry of Corporate Affairs (MCA) records.
Rikin Parekh and Paamdat Shukl serve as directors at the Company.
- CIN/LLPIN
U15117MH2011PTC211973
- Company No.
211973
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
07 Jan 2011
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Cicil Biochem?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rikin Parekh  | Managing Director | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Paamdat Shukl | Additional Director | 09-May-2024 | Current |
Financial Performance of Cicil Biochem.
Cicil Biochem Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 2.75% increase. The company also saw a substantial improvement in profitability, with a 140.36% increase in profit. The company's net worth dipped by a decrease of 0.19%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Cicil Biochem?
In 2023, Cicil Biochem had a promoter holding of 57.63% and a public holding of 42.37%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
State Bank Of India Creation Date: 29 Aug 2024 | ₹7.00 Cr | Open |
Axis Bank Limited Creation Date: 27 Aug 2024 | ₹1.71 Cr | Open |
Others Creation Date: 30 Jan 2017 | ₹14.00 Cr | Satisfied |
How Many Employees Work at Cicil Biochem?
Unlock and access historical data on people associated with Cicil Biochem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Cicil Biochem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Cicil Biochem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
